MedTrace Logo

Omacor in Prevention of Cardiovascular Events in Patients Undergoing Chronic Hemodialysis

NCT00257283 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2008-03-11

No results posted yet for this study

Summary

The aim of this investigator initated study is to examine the effect of OMACOR (Omega-3-acid ethyl ester 90) on the incidence of cardiovascular events and mortality in patients undergoing chronic hemodialysis, who has previously experienced a cardiovascular event.

Conditions

  • Kidney Failure, Chronic

Interventions

DRUG

Omega-3-acid ethyl esters 90

Sponsors & Collaborators

  • Danish Heart Foundation

    collaborator OTHER

  • The Danish Kidney Association

    collaborator OTHER

  • North Denmark Region

    collaborator OTHER_GOV

  • Pronova BioPharma

    lead INDUSTRY

Principal Investigators

  • My Svensson, MD · Department of Nephrology, Aalborg Hospital, Aarhus University Hospital, Aalborg, Denmark

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-11-30
Completion
2005-06-30

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00257283 on ClinicalTrials.gov